ZNF25 as an immunotherapy target: pan-cancer biomarker potential and mechanistic exploration in glioma
-
By
-
Xiaohong Yi
-
Xianwen Zhang
-
Lijun Huang
-
Yuhui Chen
-
Maochun You
-
Hongyi Jia
-
Lefeng Hou
-
Chao Hu
-
Kun Huang
-
Yumei Wang
-
June 2, 2026
-
Clinical Scorecard: Exploring ZNF25 as a Target for Immunotherapy: Its Potential as a Pan-Cancer Biomarker and Mechanistic Insights in Glioma
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | ZNF25 promotes glioma progression through modulation of the PI3K-AKT pathway. |
| Target Population | |
| Care Setting | |
Key Highlights
- ZNF25 is associated with poor prognosis and immune infiltration across multiple cancer types.
- Knockdown of ZNF25 inhibits proliferation and migration of glioma cells.
- Functional assays indicate ZNF25's role in glioma progression.
- Transcriptomic analysis shows ZNF25's involvement in the PI3K-AKT signaling pathway.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients diagnosed with glioma and potentially other malignancies.
Targeting ZNF25 may enhance therapeutic strategies in glioma.
Clinical Best Practices
Related Resources & Content
